Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Autor: Ahn, JB, Asselah, J, Badarinath, S, Baijal, S, Begbie, S, Berry, S, Canon, JL, Carbone, RG, Cervantes, A, Cha, YJ, Chang, K, Chaudhry, A, Chmielowska, E, Cho, SH, Chu, D, Couture, F, Cultrera, J, Cunningham, D, Van Cutsem, E, Cuyle, PJ, Davies, J, Dowden, S, Dvorkin, M, Ganju, V, Garcia, RV, Kerr, R, Kim, TY, King, K, Kortmansky, J, Kozloff, M, Lam, KO, Lee, J, Lee, AS, Lesperance, B, Luppi, G, Ma, B, Maiello, E, Mandanas, R, Marshall, J, Marx, G, Mullamitha, S, Nechaeva, M, Park, JO, Pavlakis, N, Ponce, CG, Potemski, P, Raouf, S, Reeves, J, Segal, N, Siena, S, Smolin, A, Streb, JO, Strickland, A, Szutowicz-Zielinska, E, Tabernero, JM, Tan, B, Valera, JS, Van den Eynde, M, Vergauwe, P, Vickers, M, Womack, M, Wroblewska, M, Young, R, Eng, Cathy, Kim, Tae Won, Bendell, Johanna, Argilés, Guillem, Tebbutt, Niall C, Di Bartolomeo, Maria, Falcone, Alfredo, Fakih, Marwan, Kozloff, Mark, Segal, Neil H, Sobrero, Alberto, Yan, Yibing, Chang, Ilsung, Uyei, Anne, Roberts, Louise, Ciardiello, Fortunato

Publikováno v: In The Lancet Oncology June 2019 20(6):849-861

Hedgehog Signaling Pathway in Fibrosis and Targeted Therapies.

Autor: Hu, Yuchen^1,2 (AUTHOR) huyuchen9@stu.scu.edu.cn, Peng, Linrui^1,2 (AUTHOR) linruipeng@stu.scu.edu.cn, Zhuo, Xinyu^1,2 (AUTHOR) zhuoxy@stu.scu.edu.cn, Yang, Chan³ (AUTHOR) yc199207@126.com, Zhang, Yuwei^1,2 (AUTHOR) doczhangyw@scu.edu.cn

Publikováno v: Biomolecules (2218-273X). Dec2024, Vol. 14 Issue 12, p1485. 29p.

SO-002 - Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)

Autor: Chau, I., Bendell, J., Soriano, A., Arkenau, H., Cultrera, J., Santana-Davila, R., Calvo, E., Tourneau, C. Le, Zender, L., Mi, G., Schelman, W., Ferry, D., Herbst, R., Fuchs, C.

Publikováno v: In Annals of Oncology July 2019 30 Supplement 4:iv122-iv122

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Autor: Herbst RS; Yale University School of Medicine, Yale Cancer Center, New Haven, CT, USA. Electronic address: roy.herbst@yale.edu., Arkenau HT; Drug Development Unit, Sarah Cannon Research Institute UK, London, UK; Cancer Institute, University College London, London, UK., Santana-Davila R; Drug Development Unit, University of Washington, Seattle, WA, USA., Calvo E; Early Clinical Drug Development Program, START Madrid-HM Centro Integral Oncológico Clara Campal, Madrid, Spain., Paz-Ares L; Virgen del Rocio University Hospital, Seville, Spain., Cassier PA; Centre Léon Bérard, Lyon, France., Bendell J; Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USA., Penel N; Centre Oscar Lambret, Lille, France; Department of Medical Oncology, Lille University, Lille, France., Krebs MG; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre and NIHR Manchester Clinical Research Facility, The Christie NHS Foundation Trust, Manchester, UK., Martin-Liberal J; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Catalan Institute of Oncology, Hospitalet, Barcelona, Spain., Isambert N; Centre Georges François Leclerc, Dijon, France., Soriano A; Florida Cancer Specialists, Englewood, FL, USA., Wermke M; University Hospital Carl Gustav Carus, NCT/UCC Early Clinical Trial Unit, Dresden, Germany., Cultrera J; Florida Cancer Specialists, Englewood, FL, USA., Gao L; Eli Lilly and Company, New York, NY, USA., Widau RC; Eli Lilly and Company, Indianapolis, IN, USA., Mi G; Eli Lilly and Company, Indianapolis, IN, USA., Jin J; Eli Lilly and Company, New York, NY, USA., Ferry D; Eli Lilly and Company, New York, NY, USA., Fuchs CS; Yale University School of Medicine, Yale Cancer Center, New Haven, CT, USA., Petrylak DP; Yale University School of Medicine, Yale Cancer Center, New Haven, CT, USA., Chau I; Royal Marsden Hospital, Sutton, Surrey, UK.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2019 Aug; Vol. 20 (8), pp. 1109-1123. Date of Electronic Publication: 2019 Jul 10.

PB1890: ZANUBRUTINIB IN ACALABRUTINIB‐INTOLERANT PATIENTS (PTS) WITH B‐CELL MALIGNANCIES.

Autor: Shadman, M., Flinn, I. W., Kingsley, E. C., Freeman, B., Levy, M. Y., Cultrera, J., Farber, C. M., Chaudhry, A., Porter, R., Crescenzo, R., Idoine, A., Zhang, X., Cohen, A., By, K., Huang, J., Sharman, J. P.

Publikováno v: HemaSphere; 2022 Supplement 3, Vol. 6, p1769-1770, 2p